HALO COO Cortney Caudill sells 28.9K shares for $2.0M across 3 transactions; retains 7.1K shares (80.4% position reduction)
Cortney Caudill, SVP and Chief Operating Officer of HaloZyme Therapeutics, executed 3 separate sales on 2026-03-09 and 2026-03-10, selling 28,857 shares (28.9K shares) for a combined $1,955,159.58 ($2.0M) at prices between $67.64 and $68.25 per share. This represents an 80.4% reduction in her holdings, from 35,912 shares pre-transaction to 7,055 shares post-transaction. The sales occurred near the 52-week high of $81.23, with the current price at $67.81 reflecting a -16.5% pullback from that peak over the past 30 days. HaloZyme's fundamentals remain strong, with annual revenue growth of +37.6%, net income of $175,225,000.00, and a P/E of 17.08. The substantial reduction in an executive's equity position merits scrutiny, particularly given the scope of the divestiture and the COO's operational visibility into company performance.